Please assess the completion status of the following clinical trial:

Trial Title: IRDye800CW-BBN PET-NIRF Imaging Guiding Surgery in Patients With Lower Grade Glioma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be able to provide a written informed consent~* suspected lower grade gliomas on contrast-enhanced MRI~Exclusion Criteria:~* Consisted of conditions of mental illness~* Severe liver or kidney disease with serum creatinine \> 3.0 mg/dl (270 μΜ)~* Any hepatic enzyme level 5 times or more than normal upper limit~* Severe allergy or hypersensitivity to IV radiographic contrast~* Claustrophobia to accept the PET/CT or PET/MRI scanning~* Pregnancy or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- 68Ga-BBN-IRDye800CW PET/NIRF (Type: EXPERIMENTAL): The patients were injected with 40μg/111-148 Mega-Becquerel (MBq) 68Ga-BBN-IRDye800CW in one dose intravenously and then underwent PET scan 30 min later before the operation and intraoperative 1.0 or 2.0 mg/ml BBN-IRDye800CW injected intravenously for near-infrared (NIR) fluorescent imaging-guided surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).